Research record
A research record stated with numbers and dates
AriBnC's research record in one place: six registered patents, four patent applications and two registered trademarks, the MOTIR industrial-innovation national R&D programme (agreement June 2026, 30-month term), and our current contract research agreement.
Patents and trademarks
As of October 2026 · 6 registered patents (4 acquired by transfer) · 4 applications · 2 registered trademarks
| Type | Title | Filed | Registered |
|---|---|---|---|
| Patent, registered | Composition using Lactobacillus plantarum to improve the bioavailability of vitamin C | 10-2025-0101866 26 Jul 2025 | No. 10-2947837 31 Mar 2026 |
| Patent, registered | Optical blood-glucose meter structure | 10-2023-0005723 13 Jan 2023 | No. 10-2536484 22 May 2023 |
| Patent, filed | AI-based system that predicts liver-disease indicators from non-invasive lifelog data and recommends health behaviours (joint application) | 10-2026-0099786 2 Jun 2026 | — |
| Patent, filed | Lactiplantibacillus plantarum NGM1-12-L209 strain with improved survival in the gastrointestinal tract and adhesion to intestinal epithelial cells | 10-2025-0215909 31 Dec 2025 | — |
| Patent, filed | AI-based gut microbiome profile prediction and personalised probiotics | 10-2025-0108178 Aug 2025 | — |
| Patent, filed | Health functional food composition for improving sleep | 10-2022-0186215 17 Dec 2022 | — |
| Patent, registered (transferred) | Smart scale that measures the H/Q strength ratio and gives an exercise prescription | 10-2018-0015471 8 Feb 2018 | No. 10-2036437 18 Oct 2019 |
| Patent, registered (transferred) | Composition with potato extract as the active ingredient for improving, preventing or treating muscle loss | 10-2017-0122679 22 Sep 2017 | No. 10-1961560 18 Mar 2019 |
| Patent, registered (transferred) | Composition containing green-tea and dark-tea extracts for nicotine detoxification, and its method of manufacture | 10-2018-0063092 31 May 2018 | No. 10-1900304 13 Sep 2018 |
| Patent, registered (transferred) | Pharmaceutical composition for preventing and treating depression, health functional food for relieving and improving depression, and method of manufacture | 10-2011-0049101 24 May 2011 | No. 10-1318330 8 Oct 2013 |
| Trademark, registered | BCS-001F | 40-2023-0234539 22 Dec 2023 | No. 40-2209581 17 Jun 2024 |
| Trademark, registered | BCS-002D | 40-2023-0234541 22 Dec 2023 | No. 40-2230194 5 Aug 2024 |
All filed with the Korean Intellectual Property Office (KIPO). Transferred patents are registered patents the company acquired by assignment from another rights holder. Titles are English renderings of the Korean titles on the filings and registrations; they are not claims about any product.
Research programmes in progress
Currently running: a national R&D programme, a contract research agreement, and AI prediction model work.
Study design and data management are performed at the Yongin head office laboratory; strain work is performed at the UNIST Research Institute (the UNIST site of our Corporate Affiliated Research Institute).
- MOTIR industrial-innovation national R&D programme — agreement June 2026, 30-month term
- ABCI, the AI-Bio Convergence Institute — established April 2026, AI-based prediction model research
- CRO contract with a US company — September 2026
- Research organisation — Seung Ho Jung, PhD, joined as Vice President in January 2026
Where the work is done
Papers
Fifteen of the papers AriBnC researchers have co-authored. The title links to the record on PubMed or, for papers PubMed does not index, to the journal's page.
These are academic research results; they are not a claim or an advertisement for any product. If you need papers or conference material on another subject, please ask.
The dated record — founding, recognitions and registrations, new sites — is kept in one place, on the company history page.
Frequently asked questions
Can we check the registry IDs of your studies?
Yes. For publicly registered studies, contact us and we will check and give you the registry ID.
What research material can we receive?
We can share methodology material — study design, endpoints, analysis methods, schedule. We can go into detail when we talk.
If you have a project under consideration, the type of study and your target schedule are enough to start. We first sort out whether you need the human study run (clinical), the MFDS dossier and deficiency responses as well (clinical plus regulatory), or the whole path from nonclinical onward, and come back to you.